Previous studies have indicated that ER-α can influence the activity of the MMP-13 promoter. ER-α activity is mediated by two separate transcriptional activation domains (AF-1 and AF-2). The present study focused on analyzing the roles of these domains on the activation of the MMP-13 promoter. Transfection of synoviocytes with an ER-α construct lacking the C-terminus AF-2 domain led to significant elevation in MMP-13 promoter activity compared to wild type ER-α. Progressive deletions in the N-terminal AF-1 domain led to significant losses in MMP-13 promoter activity. MMP-13 promoter mutagenesis indicated that an AP-1 regulatory site was essential for ER-α mutant activity. Thus, both AF-1 and AF-2 domains of ER-α are required for regulation of MMP-13 promoter activity. As ER variants and ER related proteins have been implicated in bone and joint disorders, these findings provide understanding of the possible role of ER variants in the development of such conditions.
INTRODUCTION
Subsets of women are prone to developing osteoarthritis (OA) following menopause when estrogen levels in the body decline (1, 2) . It is well documented that the enzyme matrix metalloproteinase 13 (MMP-13) effectively degrades collagen which is the principal constituent of cartilage, and thus may play a major role in the pathogenesis of diseases such as osteoarthritis (reviewed in 3, 4). Transgenic mice over-expressing MMP-13 show evidence of degradation of articular cartilage and exhibit joint pathology similar to those found in OA (5) .
Furthermore, studies have shown that ovariectomy of rats leads to elevations in the expression of the rodent MMP-13 in osteoblastic cells (6) .
The expression of MMP-13 is low in the cartilage of normal skeletally mature adults and this likely enables healthy connective tissue remodeling without damaging the tissues (7).
However, in osteoarthritis-like conditions the level of MMP-13 expression increases considerably (including in synovium), resulting in aberrant destruction of cartilage tissue (7, 8, 9, 10) . Based on its importance in normal and disease states, better understanding of the potential mechanisms by which MMP-13 expression is regulated by ER-α (+/-estrogen) may provide valuable insights into the onset and progression of OA, particularly in a subset of postmenopausal females.
The detection of estrogen receptors (ER) in several tissues of the joint indicates that these tissues are likely responsive to the hormone estrogen. Several studies have established the presence of both MMP-13 and ER in joint tissues (11, 12, 13, 14, 15) and parallel in vitro studies have indicated that both alpha and beta isoforms of ER (ER-α and ER-β) can elevate the activity of the MMP-13 promoter and this modulation is decreased depending upon whether or not the ER-α or ER-β is complexed with estrogenic ligands (16, 17) . It is well established from previous studies that both the alpha and beta isoforms of ER function as ligand-inducible transcription factors and regulate the expression of estrogen responsive genes (reviewed in 18, 19) . Transcriptional activation or repression of genes by ER occurs through the estrogen
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response element (ERE) or through ER tethering to other transcription factors that act through the AP-1 or other transcriptional regulatory sites often present in the promoter (20, 21) . Recent studies have shown that ER-α can regulate the expression of a member of the matrix metalloproteinase family of genes -MMP-13, primarily through the AP-1 transcriptional regulatory site (16) .
ER-α is a modular protein that is comprised of six functional domains denoted A-F, each with specific functions, such as ligand binding, dimerization and DNA binding and transactivation. The activating potential of ER-α is mediated by two separate transcriptional activation domains (AF-1 and AF-2) that allow it to stimulate the transcription of specific genes (22) . The relative activities of the AF-1 and AF-2 domains of ER-α vary depending upon the cellular environment and the promoter of the specific regulated gene. Furthermore, since the AF-1 and AF-2 domains are located at the amino and carboxyl terminal ends of the protein, respectively, synergism between the two AF sites via coactivators may also play a role in exerting their influence on downstream promoters (23) .
Further to this discussion, naturally occurring variants of ER that lack the ligand binding exon, apparently through alternative splicing, have been reported in breast cancer tissue (24) and in ligaments (11) . In addition, a family of estrogen receptor related proteins (ERR), also lacking ligand binding potential have been described in bone and other tissues (25) . Recent studies have indicated that expression of some of these ERR can be modulated in joint tissues during inflammatory joint disease development (26) . Therefore, not only is it of interest to understand the basic biology of ER variants, there may also be clinical relevance to their presence.
The presence or absence of estrogen has an influence not only on the MMP-13 activity in synoviocytes (16) , but also on other MMPs such as MMP-2, MMP-7 and MMP-9 which are expressed in tissues such as the cornea (27) . With the aim of increasing our understanding of the role of ER in regulation of MMP-13, in the present study we have analyzed the roles of the
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promoter in the presence and absence of estrogen in a rabbit synoviocyte cell line.
Methods and Materials
Cell culture ---The rabbit synoviocyte cell line HIG-82 was obtained from the American Type Culture Collection (Rockville, Md). Cells were maintained at 37°C under 5% CO2 in Ham's F-12
Nutrient Media (Life technologies) supplemented with 10% Fetal calf serum (InVitrogen Canada
Inc.) and 1% Penicillin/Streptomycin. Cells were subcultured 1:4 with 0.25% trypsin. This cell line was previously shown to be negative for endogenous ER-α and ER-ß expression (16, 17) .
Construction of rabbit MMP-13 Luciferase reporter vector --
The promoterless pGL2 Basic luciferase reporter vector (Promega, Madison, WI) was used to construct a plasmid containing the proximal 370bp of the rabbit MMP-13 promoter. The MMP-13 promoter construct p370-Luc was generated by PCR using a 5'-sense primer containing the appropriate MMP-13 promoter sequence with a Kpn-I site introduced at the 5'-end and the same 3'-antisense primer 5'-CCAACAGTACCGGAATGCCAAGC-3' (nucleotide 49 to 71) that corresponds to a pGL2 Basic sequence downstream of the multiple cloning site. The 5'-primer used for p370-Luc construct contained MMP-13 sequence (underlined) was -370 to -356 (5'-CGGGTACCATGGGCGTACACATA-3').
PCR products were purified and precipitated by the QIA quick-spin PCR purification kit (Qiagen) and digested with KpnI/HindIII. The final product was then ligated into KpnI/HindIII digested pGL2 Basic and transformed into E.coli (DH-5α). Mutations were introduced into desired constructs using the Quick Change Site-Directed Mutagenesis kit (Stratagene). The mutagenic oligonucleotide primers were designed and synthesized for each mutant. The AP-1 site TGACTCA was changed by mutating TGA to ACT at the first three bases. The PEA-3 site consensus sequence AGGAAGC was altered to AACAAGC and the Runx domain binding
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sequence (RD site) AACCACA was changed to AGACACA. All reporter plasmids were purified on EndoFree Plasmid Maxi Kits (Qiagen, Mississauga, ON) according to the manufacturer's instructions and subjected to sequencing analysis to verify the orientation and accuracy of each construct.
Additional Control and ER-α Expression Plasmids --The internal control plasmid pRLSV40
was obtained from Promega (Promega, Madison, WI). The pRLSV40 plasmid constitutively expresses the Renilla form of luciferase under the strong SV40 promoter and thereby acts as an internal control in the dual luciferase assay. The expression vectors for ER-α such as WT-ERα, E41, A87, M109, ΔAB and ABCD were those used previously and were all subcloned into the same vector, pCMV5 (28) .
Subcloning of ΔAB, ABCD into the pSG5 vector -The ΔAB and ABCD constructs were subcloned from pCMV5 (28) to the pSG5 vector (Stratagene, USA). The sequence and orientation of the sub-cloned fragments was confirmed by sequencing. 
Transient Transfection and Luciferase assay --
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washed with PBS, total RNA was isolated using the TRIspin method (29) and then the SYBR ® Green reagent was subsequently used for fluorometric quantification of total RNA. One microgram of total RNA from each sample was reverse transcribed using the Omniscript RT kit (Qiagen Inc., Mississauga, ON) using random primers and Omniscript reverse transcriptase, and diluted to 500 µL/µg RNA. All samples in an experiment were subjected to RT at the same time to avoid variability. fluorescence. The specificity of the PCR amplification was checked by examining the melting curve (dF/dT vs temperature) for non-specific peaks. GAPDH levels were used as a reference for normalization and relative quantification was analyzed using iCycler iQ Optical System Software Version 3.0a (Bio-Rad, Hercules, CA).
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Statistical Analysis: Statistical analysis of the data was performed using ANOVA, STDEVA, and STEYX in the Excel 5.0 software. Therefore, the increased or decreased levels of MMP-13 activity observed when ABCD or ΔAB is the modulator is likely not due to overtly unequal expression of ER-α mutants. 1µg, along with the p370-Luc MMP-13 promoter and the internal control plasmid, pRLSV40 (see Figure 2B ). After 24 hours, the luciferase activities of the cell lysates were determined.
Results
Protein levels of WT-ERα
Comparing the influence of increasing concentration of WT-ERα
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The results presented in Figure 2B demonstrate that increasing concentrations of ABCD and WT-ERα DNA led to corresponding elevations in MMP-13 promoter activity. MMP-13 activity was elevated to a greater extent under the influence of ABCD compared to WT-ERα.
MMP-13 promoter activity was increased by ~30 fold by 1 µg of ABCD when present as the modulator, while only a ~10 fold increase was observed with the same concentration of WT-ERα (see Figure 2B ). In general, MMP-13 promoter activity was elevated ~ 3 to 4 fold higher when the ABCD mutant of ER-α was the modulator as compared to the WT-ERα, across the concentration range assessed. HIG-82 cells transfected with only the p370-Luc construct (1.0 µg) and the internal control plasmid, pRLSV40 (0.05 µg) were used as a control and very low levels of MMP-13 activity were detected. These results indicate that when the AF-2/Ligand binding domains were deleted from ER-α constructs, a greater stimulation of MMP-13 promoter activity was observed than with equivalent doses of WT-ERα.
Comparing the influence of increasing concentration of WT-ERα and ΔAB DNA on
MMP-13 promoter activity
Next, the effect of increasing concentrations of WT-ERα DNA was compared with the influence of ΔAB on MMP-13 promoter activity. HIG-82 cells were transiently transfected with either WT-ERα or ΔAB at increasing DNA concentrations ranging from 0 -1 µg, concurrent with the p370-Luc construct (1.0 µg) and the internal control plasmid, pRLSV40 (0.05 µg). After 24 hours, the luciferase activity of the cell lysates were determined. In the absence of exogenous WT-ERα or ΔAB, minimal MMP-13 promoter activity was again detectable (see Figure 3) .
The results presented in Figure 3 demonstrate that increasing concentrations of WT-ERα DNA again led to corresponding elevations in MMP-13 promoter activity. However, no significant stimulation in MMP-13 promoter activity was observed when ΔAB was the modulator, even when ΔAB levels were increased to 1 µg. In contrast, in the positive controls a 5-fold increase in MMP-13 promoter activity was observed when 0.25 µg of WT-ERα was used.
Furthermore, increasing the amount of WT-ERα DNA, to 0.5 and 1 µg led to ~ 9 and ~ 11 fold
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elevations in the activity of MMP-13 (See Figure 3) . These results indicate that the presence of the AF-1 domain of ER-α is essential for up-regulating the activity of the MMP-13 promoter. These constructs were evaluated using transient transfection assays in HIG-82 cells.
Influence
The HIG-82 cells were transfected with p370-Luc (1 µg), one of the deletion constructs of AF-1 domain of ER-α (0.5ug) and the internal control plasmid, pRLSV40 (0.05ug) following the FuGene 6 transfection protocol. After 24 hours, the transfected cells were lysed and analyzed for MMP-13 promoter activity using luciferase assays.
The MMP-13 promoter activity observed with WT-ERα was set at 100% as presented in Figure 5B . When the E41 construct of ER-α was used, a mean 23% decrease in MMP-13
promoter activity was observed. Use of the A87 deletion construct led to a mean 55% decrease in MMP-13 promoter activity. Increasing the extent of the deletion in the AF-1 domain (M109 construct) led to a mean 63% decrease in MMP-13 promoter activity, and complete elimination of the AF-1 domain led to a mean 70% decrease in MMP-13 promoter activity. These results
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indicate that progressive deletions across the AF-1 domain of ER-α lead to an increasing loss in the ability of ER to regulate MMP-13 promoter activity. However, even the complete removal of the AF-1 failed to completely eliminate ER influence on MMP-13 promoter activity, suggesting minor roles for other domains of ER-α. 
A. Modulation of MMP-13 promoter activity by WT-ERα
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In the presence of WT-ERα, the MMP-13 promoter constructs exhibited varying degrees of activity proportional to the presence and role of each regulatory site. Maximum activity of the promoter was achieved when the MMP-13 promoter construct (p370-Luc) contained all the known transcription factor binding sites -the Runx, p53, PEA-3 and AP-1 sites. The activity level of cells transfected with wild type MMP-13 promoter (p370-Luc) was used as a control for this experiment and activity was set at 100%.
Site directed mutations in the Runx domain changed the normal Runx site of (AACCACA) to (AGACACA). As shown in Figure 6 B, a 22% decrease in luciferase activity was observed when only the Runx site was mutated (M370R2) compared to the activity levels of WT370 (Figure 6 B).
The promoter activity of WT370 decreased by 60% when 17-β estradiol was present (Figure 6 B ).
In the presence of estradiol, the residual promoter activity of M370R2 decreased by 43%, compared to its activity in the absence of ligand (Figure 6 B) .
Mutations in the PEA-3 site, which changed the sequence from AGGAAGC to AACAAGC (M370P2), resulted in a ~25% decrease in activity of the MMP-13 promoter when compared to control values (Figure 6 B) . Addition of estradiol led to a ~52% decline in residual M370P2 activity as compared to its activity in the absence of any ligand. These results indicate that mutation in either the Runx or the PEA-3 site leads to similar decreases in MMP-13 promoter activity, and that estradiol was still an effective modulator of ER activity.
The AP-1 site was mutated in M370A3 and three bases were mutated to change the sequence from TGACTCA to ACTCTCA. A significant reduction in the activity of the MMP-13
promoter was observed (~87%) when the AP-1 domain was mutated as compared to the WT370
values (see Figure 6 B ). Furthermore, under the influence of 17-β estradiol a further ~50% reduction in the residual activity of the M370A3 promoter was observed (see Figure 6 B ).
Subsequently, the effect of mutating all three of the regulatory sites in the same construct was examined. Even when all three sites, i.e. AP-1, PEA-3 and Runx (M370A3P2R2) were mutated, MMP-13 promoter activity was depressed by ~86%, which is nearly identical to that
observed for the AP-1 mutant alone (~87%). These results indicate that AP-1 is likely the major element in regulating MMP-13 promoter activity in response to WT-ERα, and other domains such as Runx and PEA-3 play minor roles in modulating its activity.
B. Modulation of MMP-13 promoter activity By ΔAB
As shown in Figure 6 C, the activity levels of WT370 modulated by ΔAB in the absence of any ligand was set at 100%. A ~50% decrease in the WT370 activity level was observed when 17-β estradiol was present (see Figure 6C) . Therefore, the residual activity of ΔAB on the MMP-13 promoter was still mainly mediated via the AP-1 site.
C. Modulation of MMP-13 promoter activity By ABCD
As exhibited in Figure 6 D, promoter activity levels were the highest when all the transcriptional regulatory elements were intact as in the WT370 MMP-13 promoter construct, and when the ABCD mutant of ER-α was the modulator, and this was not altered in the Furthermore, no decreases in the activity of either the WT370 or the mutant M370R2, M370P2 and M370A3 promoters was observed in the presence of the ligand, 17-β estradiol when ABCD was the modulator (See Figure 6D) . These results again indicate that the ABCD construct is unable to respond to 17-β estradiol and that the AP-1 regulatory site of MMP-13 is the major regulatory site required for mediating the effects of ABCD (+/-) ligand.
Discussion
The results presented in this study in synoviocyte cells suggest that both AF-1 and AF-
/ ligand binding domains of ER-α play a role in modulating the activity of the MMP-13
promoter. Complete deletion of the AF-1 domain of ER-α (ΔAB construct) led to significant reductions in MMP-13 promoter activity when compared to the influence of WT-ERα on MMP-13 activity (see Figure 3B ). Since the AF-2 / ligand binding domain is intact in the ΔAB construct, it is still able to mediate the effects of the ligand, 17-β estradiol, and addition of the hormone led to decreases in the residual MMP-13 promoter activity (see Figure 4C ). Conversely, a constitutive elevation in the activity of the MMP-13 promoter was observed when the ABCD mutant ER with a deletion of the AF-2/ligand binding domain was used as the modulator. As Moreover, it is also well recognized that the activation function of both the AF-1 and AF-2 domains of ER-α vary in a promoter and cell type specific manner (30, 31, 32) . Previous reports have shown that the activity of the AF-2 domain is controlled by the hormone, estrogen (30) . In the present studies, MMP-13 promoter activity was found to be very low when ΔAB was the modulator as compared to the influence of the WT-ERα (see Figure 3B) . The ΔAB is a deletion mutant of ER-α which is missing the entire AF-1 domain. The AF-1 domain is well characterized as the ligand independent transactivation domain of the ER-α and is speculated to synergize with the AF-2 domain to elicit the overall estrogen response on promoters
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containing classical estrogen response elements (ERE) (30, 34, 20) . Recently, it was shown that the cyclin G2 gene is down-regulated by ER-α when it is occupied by estrogen (35) . • P < 0.05 when compared to WT370 activity modulated by WT-ERα ‡ P < 0.005 when compared to WT370 activity modulated by WT-ERα P < 0.0005 Comparison of promoter activity of WT370 and mutants (+/-17-β estradiol) C. HIG-82 cells were transiently co-transfected with wild-type and site-directed mutant constructs of rabbit MMP-13 promoter, ABCD -a mutant construct of ER-α and internal control plasmid, pRLSV40. Cells were treated with 10 
